It’s a trial setting for sure, so prospectively enroll patients and follow their outcome. FLHCC patients usually get excluded form trials for HCC, given their different natural history and disease course. This is also applicable to transplant setting. One can argue to proceed if the tumors mee...

We would offer a transplant to a pediatric patient, but only as a last resort—instead we would try to do liver sparing surgery, shrink the tumor first with systemic therapy or with IR procedures such as TARE or do PVE do induce insitu hypertrophy of uninvolved segments—all of these optio...

Not aware of any supporting data. Scientific argument is not there. The liver is healthy, and not cirrhotic. Need to target the genetic alterations. Clinical trials are limited, but are there at Sloan Kettering, Dana Farber, and UCSF,